Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

OBJECTIVE: The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. METHODS: This multicentre, double-blind study randomized patients with active primary or secondary SS [EULAR SS disease activity index (ESSDAI) ≥5) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Elizabeth, Bombardieri, Michele, Kivitz, Alan, Matzkies, Franziska, Gurtovaya, Oksana , Pechonkina, Alena, Jiang, Wendy, Downie, Bryan, Mathur, Anubhav, Mozaffarian, Afsaneh, Mozaffarian, Neelufar, Gottenberg, J Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707320/
https://www.ncbi.nlm.nih.gov/pubmed/35377447
http://dx.doi.org/10.1093/rheumatology/keac167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707320/
https://www.ncbi.nlm.nih.gov/pubmed/35377447
http://dx.doi.org/10.1093/rheumatology/keac167

Ejemplares similares